Abstracts tagged "Cardiovascular disease and rheumatoid arthritis (RA)"

Abstract Number: 422 • 2013 ACR/ARHP Annual Meeting
Disease Activity In Rheumatoid Arthritis Is Associated With Abnormal Left Ventricular Geometry
Helga Midtbø¹, Eva Gerdts^1,2, Inge C. Olsen³, Tore K. Kvien⁴, Einar Davidsen¹ and Anne Grete Semb³, ¹Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, ²Department of Cinical Science, University of Bergen, Bergen, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose :Disease activity is related to risk of cardiovascular (CV) disease in rheumatoid arthritis (RA) patients1,2. Left ventricular (LV) geometry strongly predicts CV mortality and…
Abstract Number: 404 • 2013 ACR/ARHP Annual Meeting
Arterial Stiffness Is Associated With Abnormal Left Ventricular Geometry In Patients With Rheumatoid Arthritis
Helga Midtbø¹, Eva Gerdts^1,2, Inge C. Olsen³, Tore K. Kvien⁴, Einar Davidsen¹ and Anne Grete Semb³, ¹Department of Heart Disease, Haukeland University Hospital, Bergen, Norway, ²Department of Cinical Science, University of Bergen, Bergen, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rheumatoid arthritis (RA) predisposes for increased arterial stiffness(1). In hypertension, arterial stiffness is a powerful modulator of left ventricular (LV) geometry(2). Whether this is…
Abstract Number: 406 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Case Fatality In Rheumatoid Arthritis Is Decreasing; Results From a Current Low Disease Activity Rheumatoid Arthritis Cohort and Review Of The Literature
Inger L. Meek¹, Harald E. Vonkeman² and Mart A.F.J. van de Laar³, ¹Rheumatology & Clinical Immunology, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ²Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, ³Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality. Previous studies, found increased case fatality after myocardial infarction and more frequent…
Abstract Number: 360 • 2013 ACR/ARHP Annual Meeting
Visit-To-Visit Variability In Blood Pressure In Patients With Rheumatoid Arthritis (RA) Vs General Population, and Its Impact On Cardiovascular Events and All-Cause Mortality In RA
Elena Myasoedova¹, Cynthia S. Crowson², Abigail B. Green², Eric L. Matteson³ and Sherine E. Gabriel⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Blood pressure (BP) variability has been associated with increased risk of cardiovascular (CV) disease and death in the general population. The impact of BP…
Abstract Number: 368 • 2013 ACR/ARHP Annual Meeting
Detrimental Impact Of Long-Term Cumulative Burden Of Rheumatoid Arthritis (RA) Disease Severity On Cardiovascular Outcomes In RA
Elena Myasoedova¹, Birkan Ilhan², Helen Khun³, Eric L. Matteson⁴ and Cynthia S. Crowson³, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Several studies have shown the associations of various measures of rheumatoid arthritis (RA) disease severity with unfavorable cardiovascular (CV) outcomes in RA. The association…
Abstract Number: 369 • 2013 ACR/ARHP Annual Meeting
Prolongation Of QT Interval In Patients With Rheumatoid Arthritis and Its Impact On Mortality: Results From a Population-Based Study
Krati Chauhan¹, Michael Ackerman², Cynthia S. Crowson³, Eric L. Matteson¹ and Sherine E. Gabriel⁴, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Division of Cardiology, Mayo Clinic, Rochester Minnesota, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular morbidity and mortality. This risk persists even when RA disease characteristics are taken…
Abstract Number: 356 • 2013 ACR/ARHP Annual Meeting
Outcomes Of Patients With Rheumatoid Arthritis and Comorbid Hyperlipidemia
L Rosenblatt¹, JR Curtis², G Yang¹ and T Hebden³, ¹Bristol-Myers Squibb, Plainsboro, NJ, ²University of Alabama at Birmingham, Birmingham, AL, ³Formerly of Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Patients (pts) with RA have an increased prevalence of cardiovascular disease (CVD). Whether due to comorbidity or related to RA medications, many pts with…
Abstract Number: 116 • 2013 ACR/ARHP Annual Meeting
Lack Of Association Between Preclinical Markers For Cardiovascular Disease and Rheumatoid Arthritis-Related Autoimmunity In First-Degree Relatives Without Rheumatoid Arthritis
Jill M. Norris¹, Ryan W. Gan¹, Jan M. Hughes-Austin², Kevin D. Deane³, M. Kristen Demoruelle³, Elaine M. Urbina⁴, Kerrie Moreau⁵, Peter K. Gregersen⁶, Michael H. Weisman⁷ and V. Michael Holers⁸, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Preventive Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Medicine, University of Colorado School of Medicine, Aurora, CO, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is characterized by systemic inflammation and immune dysregulation, including the presence of autoantibodies and elevated inflammatory biomarkers in subjects with classifiable…
Abstract Number: L5 • 2013 ACR/ARHP Annual Meeting
Improvement in High Density Lipoprotein Function in Early Rheumatoid Arthritis Patients Treated with Methotrexate Monotherapy or Combination Therapy in the Treatment of Early Rheumatoid Arthritis Trial
C. Charles-Schoeman¹, Yuen Yin Lee¹, Ani Shahbazian¹, David Elashoff², Xiaoyan Wong³, Jeffrey R. Curtis⁴, Iris Navarro-Millan⁵, Shuo Yang⁶, Lang Chen⁴, Stacey Cofield⁷, Larry W. Moreland⁸, Harold E. Paulus¹, James O' Dell⁹, Joan M. Bathon¹⁰, S. Louis Bridges Jr.¹¹ and Srinivasa T. Reddy¹², ¹Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ³Medicine-Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹⁰Columbia University, New York, NY, ¹¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹²Medicine-Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Abnormal function of high density lipoprotein (HDL) has been implicated as a potential mechanism for the increased cardiovascular disease (CVD) in patients with rheumatoid…
Abstract Number: 1248 • 2012 ACR/ARHP Annual Meeting
Accelerated Aging Influences Cardiovascular Disease Risk in Rheumatoid Arthritis
Cynthia S. Crowson¹, Terry M. Therneau¹, John M. Davis III², Veronique L. Roger³, Eric L. Matteson² and Sherine E. Gabriel⁴, ¹Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research and Cardiology, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: People with rheumatoid arthritis (RA) suffer an excess burden of cardiovascular disease (CVD), yet standard risk assessments designed for the general population do not…
Abstract Number: 1205 • 2012 ACR/ARHP Annual Meeting
Study of Association of CD40-CD154 Gene Polymorphisms with Disease Susceptibility and Cardiovascular Risk in Spanish Rheumatoid Arthritis Patients
Mercedes García-Bermúdez¹, Carlos González-Juanatey², Alfonso Corrales³, Raquel López-Mejías⁴, Maria Teruel⁵, Jose A. Miranda-Filloy⁶, Santos Castañeda-Sanz⁷, Alejandro Balsa⁸, B. Fernández-Gutierrez⁹, Isidoro González-Álvaro¹⁰, Carmen Gómez-Vaquero¹¹, R. Blanco Alonso¹², Javier Llorca¹³, Javier Martin¹⁴ and Miguel Angel González-Gay⁴, ¹Immunology and Cellular Biology, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ²Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ⁶Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. Madrid. Spain, Madrid, Spain, ⁸Rheumatology, La Paz Hospital. IdiPaz, Madrid, Spain, ⁹Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Servicio de Reumatología, Reumatología (Hospital Universitario de La Princesa), Madrid, Spain, ¹¹Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ¹²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹³Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ¹⁴Immunology, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased cardiovascular (CV) mortality. Since CD40-CD154 binding has direct consequences on inflammation process initiation,…
Abstract Number: 1211 • 2012 ACR/ARHP Annual Meeting
ANTI-Cyclic Citrullinated Protein Antibodies Induce Inflammation and Oxidative Stress in WHITE Blood CELLS of Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Carlos Perez-Sanchez¹, Patricia Ruiz-Limon¹, Mª Angeles Aguirre², Rosario M. Carretero-Prieto¹, Antonio Rodriguez-Ariza³, Nuria Barbarroja¹, Pilar Font¹, Francisco Martinez², Inmaculada Gomez-Gracia², Mª Jose Cuadrado⁴ and Eduardo Collantes-Estevez², ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: Anti-cyclic citrulinated protein antibodies (anti-CCP) are the most specific autoantibody markers in rheumatoid arthritis (RA) patients. However no previous studies have evaluated their role…
Abstract Number: 829 • 2012 ACR/ARHP Annual Meeting
Subcutaneous Nodules Are Significantly Associated with Cardiovascular Events in Patients with Rheumatoid Arthritis: Results From a Very Large US Registry
Prashant Kaushik¹, Susan P. Messing², Jyoti Arora², George Reed³, Katherine C. Saunders⁴, Jeffrey D. Greenberg⁵ and Joel M. Kremer⁶, ¹Department of Medicine, Sratton VAMC, Albany, NY, ²Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, ³Division of Behavioral and Preventive Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Corrona, LLC., Southborough, MA, ⁵New York Hospital for Joint Disease, New York, NY, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Cardiovascular Disease (CVD) is now recognized to be a major comorbidity of patients with rheumatoid arthritis. Predictors of CVD have been shown to include…
Abstract Number: 71 • 2012 ACR/ARHP Annual Meeting
The Association Between Preclinical Markers for Cardiovascular Disease and Rheumatoid Arthritis-Related Autoantibodies in First-Degree Relatives without Rheumatoid Arthritis
Ryan W. Gan¹, Jan M. Hughes-Austin², Kevin D. Deane³, Elaine M. Urbina⁴, Peter K. Gregersen⁵, Michael H. Weisman⁶, V. Michael Holers⁷ and Jill M. Norris¹, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Epidemiology, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Preventive Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is characterized by systemic inflammation and immune dysregulation, including the presence of autoantibodies and elevated inflammatory markers in subjects with…
Abstract Number: 2539 • 2012 ACR/ARHP Annual Meeting
Fine-Specificity of Anti-Citrullinated Peptide Auto-Antibodies: Associations with Cardiac Structure and Function in Rheumatoid Arthritis
Laura Geraldino-Pardilla¹, Jon T. Giles², Jeremy Sokolove³, William H. Robinson⁴ and Joan M. Bathon⁵, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁴Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁵Columbia University, New York, NY
Background/Purpose: Despite advancements in rheumatoid arthritis (RA) treatment, standardized mortality rates remain up to 3 times higher than in the general population. Cardiovascular disease (CVD)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].